试验发现,添加伦瓦替尼与布罗利祖马布和化疗并没有提高晚期食道癌的存活率. Adding lenvatinib to pembrolizumab and chemo didn’t boost survival in advanced esophageal cancer, trial finds.

在2025年ESMO大会上提出的一项第三期试验发现,添加lenvatinib与pembrolizumab和化疗并没有改善晚期食道状细胞癌的整体存活率,与单独使用pembrolizumab和化疗相比,平均存活率为17. 6个月,而15. 5个月. A phase 3 trial presented at the 2025 ESMO Congress found that adding lenvatinib to pembrolizumab and chemotherapy did not improve overall survival in advanced esophageal squamous cell carcinoma compared to pembrolizumab plus chemotherapy alone, with median survival of 17.6 vs. 15.5 months. 试验包括约850名患者,并没有显示包括PD- L1状态在内的各个亚组有显著益处. The trial included about 850 patients and showed no significant benefit across subgroups, including PD-L1 status. 伦瓦蒂尼布群体无进步存活率略高,但统计意义不大。 Progression-free survival was slightly higher in the lenvatinib group but not statistically significant. CheckMate 648试验的最新结果显示,同一类癌症的5年存活率和反应耐久性显著提高。 Updated results from the CheckMate 648 trial showed nivolumab combined with chemotherapy or ipilimumab significantly improved 5-year survival and response durability in the same cancer type.